Table 2.
Baseline characteristics in patients with non-AD and mild-to-moderate AD patients in 2017 prior to propensity score matching in THIN
| Baseline characteristic | Non-AD n (%) |
Mild-to-moderate AD patients n (%) |
|---|---|---|
| Overall | 2,606,242 (100) | 33,749 (100) |
| Age 0–7 | 192,771 (7.40) | 10,377 (30.75) |
| Age 8–11 | 123,919 (4.75) | 2254 (6.68) |
| Age 12–17 | 163,917 (6.29) | 2525 (7.48) |
| Age 18 + | 2,125,635 (81.56) | 18,593 (55.09) |
| Male | 1,305,224 (50.08) | 15,199 (45.04) |
| Female | 1,301,018 (49.92) | 18,550 (55.96) |
| England | 1,018,607 (39.08) | 14,440 (42.79) |
| Northern Ireland | 228,366 (8.76) | 2478 (7.34) |
| Scotland | 783,174 (30.05) | 7735 (22.92) |
| Wales | 576,095 (22.1) | 9096 (26.95) |
AD patients in each time period were identified in THIN based on GP diagnosis of AD, continuous disease activity from 2013 to 2017 and sufficient patient status to fully validate data integrity for the entire time period. A published algorithm defined in a UK-based study was used to exclude severe patients and capture mild-to-moderate AD patients; Non-AD controls in each time period were identified in THIN based on the same criteria as AD patients except for the presence of AD diagnosis
AD atopic dermatitis, THIN The Health Improvement Network